Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.6 EUR
16.40 M EUR
101.10 M EUR
2.39 M
About PHARMASGP HOLDING SE
Sector
CEO
Natalie Weigand
Headquarters
Graefelfing
Website
Founded
2019
ISIN
DE000A2P4LJ5
FIGI
BBG00V7RKVL0
PharmaSGP Holding SE engages in the sale and marketing of non-prescription drugs, chemical-free over-the-counter painkillers, as well as herbal medicines. It distributes its products under the Baldriparan, Formigran, Spalt, Kamol, RubaXX, Restaxil, DESEO, and NERADIN brands. The company was founded in 2012 and is headquartered in Graefelfing, Germany.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PSG is 24.4 EUR — it has increased by 1.67% in the past 24 hours. Watch PHARMASGP HOLDING SE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange PHARMASGP HOLDING SE stocks are traded under the ticker PSG.
PSG stock has fallen by −2.40% compared to the previous week, the month change is a −3.94% fall, over the last year PHARMASGP HOLDING SE has showed a 12.96% increase.
We've gathered analysts' opinions on PHARMASGP HOLDING SE future price: according to them, PSG price has a max estimate of 39.50 EUR and a min estimate of 38.00 EUR. Watch PSG chart and read a more detailed PHARMASGP HOLDING SE stock forecast: see what analysts think of PHARMASGP HOLDING SE and suggest that you do with its stocks.
PSG stock is 3.36% volatile and has beta coefficient of −0.15. Track PHARMASGP HOLDING SE stock price on the chart and check out the list of the most volatile stocks — is PHARMASGP HOLDING SE there?
Today PHARMASGP HOLDING SE has the market capitalization of 292.56 M, it has increased by 0.84% over the last week.
Yes, you can track PHARMASGP HOLDING SE financials in yearly and quarterly reports right on TradingView.
PHARMASGP HOLDING SE is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
PSG earnings for the last quarter are 0.45 EUR per share, whereas the estimation was 0.47 EUR resulting in a −4.26% surprise. The estimated earnings for the next quarter are 0.47 EUR per share. See more details about PHARMASGP HOLDING SE earnings.
PHARMASGP HOLDING SE revenue for the last quarter amounts to 30.20 M EUR, despite the estimated figure of 30.30 M EUR. In the next quarter, revenue is expected to reach 26.60 M EUR.
PSG net income for the last quarter is 5.37 M EUR, while the quarter before that showed 4.12 M EUR of net income which accounts for 30.48% change. Track more PHARMASGP HOLDING SE financial stats to get the full picture.
Yes, PSG dividends are paid annually. The last dividend per share was 1.36 EUR. As of today, Dividend Yield (TTM)% is 5.57%. Tracking PHARMASGP HOLDING SE dividends might help you take more informed decisions.
PHARMASGP HOLDING SE dividend yield was 6.04% in 2023, and payout ratio reached 99.47%. The year before the numbers were 1.84% and 49.19% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 29, 2024, the company has 89.00 employees. See our rating of the largest employees — is PHARMASGP HOLDING SE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMASGP HOLDING SE EBITDA is 36.36 M EUR, and current EBITDA margin is 33.72%. See more stats in PHARMASGP HOLDING SE financial statements.
Like other stocks, PSG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMASGP HOLDING SE stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMASGP HOLDING SE technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMASGP HOLDING SE stock shows the buy signal. See more of PHARMASGP HOLDING SE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.